Browse

Search for: rheumatoid arthritis    methotrexate    autoimmune disease    biomarker    gene expression    GWAS    HLA genes    non-HLA genes   

ID PMID Title PublicationDate abstract
19386610 Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate 2009 Dec OBJECTIVE: To examine the effect of infliximab plus methotrexate (MTX) compared with placebo plus MTX on bone loss in patients with early rheumatoid arthritis (RA) in a double-blind randomised study design. Further, to explore the associations between bone loss and markers of RA disease. METHODS: All 20 patients with RA (10 patients in each treatment group) had active, early RA. Bone mineral density (BMD) was assessed at the hand, lumbar spine (L2-4) and hip by dual energy x-ray absorptiometry at baseline and 12 months' follow-up. Clinical data were collected at regular visits. RESULTS: BMD loss was significantly reduced in the infliximab group compared with the placebo group at the femoral neck (-0.35% vs -3.43%, p = 0.01) and total hip (-0.23% vs -2.62%, p = 0.03) but not at the hand (-2.09% vs -2.82%, p = 0.82) and spine (-0.75% vs -1.77%, p = 0.71). Measures of disease process and joint damage were found to be independently associated with bone loss. CONCLUSIONS: This study provides strong evidence of a causal link between inflammation and bone loss in RA. The anti-inflammatory effect of infliximab was potent enough to arrest inflammatory bone loss at the hip but not at the spine and hand.
20518145 Anemia versus disease activity as cause of fatigue in rheumatoid arthritis. 2010 Jan BACKGROUND: Fatigue is a common complaint in rheumatoid arthritis patients and contributes to loss of quality of life. OBJECTIVE: To study the influence of hemoglobin levels and disease activity index upon fatigue in patients with rheumatoid arthritis (RA). METHODS: We studied 130 RA patients for DAS 28, hemoglobin levels and fatigue as measured by FACIT F. RESULTS: No association between fatigue with hemoglobin levels was observed. A positive association with DAS-28 was found. Decomposing DAS-28, no association could be detected with sedimentation rate but a positive correlation with analogical scale for general health, number of swollen and painful joints was found. CONCLUSION: Although a positive association of fatigue with DAS-28 is found it appears that the most important items in connection with fatigue are swollen and tender joints as well as general health status. Hemoglobin levels were not related to fatigue in our patients.
21153824 Comparison of foot pain and foot care among rheumatoid arthritis patients taking and not t 2011 Nov Epidemiological studies report foot pain affects more than 90% of people with rheumatoid arthritis (RA). Most data about foot involvement in RA were collected prior to the availability of novel treatments such as biologics. The objective of this study is to compare the prevalence of foot symptoms, frequency of foot examination, and access to foot care services among RA patients currently treated with anti-TNFα to those not receiving biologics. This study is a cross-sectional epidemiological study: a 28-item self-administered questionnaire was posted to 1,040 people with RA throughout the UK. Overall, 585 (55%) useable replies were received, and 120 (20.5%) respondents were currently taking anti-TNFα medication. Prevalence of current foot pain was 99% among the biologics group compared with 76% not treated with biologics. Stiffness, swelling, and numbness in the feet were all significantly more common in the anti-TNFα group (P < 0.05). Most respondents (90%) taking biologics discussed their foot pain with their rheumatologist, but only 70% were receiving podiatry (compared to 78% not taking anti-TNFα). Subjects reported that their feet were examined significantly less frequently (P < 0.001) than their hands. Foot complaints are common in this group, and allied health professions could enhance rheumatological care by undertaking foot assessment.
20097931 Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. 2010 Jul Tocilizumab is a humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody that has demonstrated efficacy in the treatment of rheumatoid arthritis (RA). A population pharmacokinetic (PK) model was developed using nonlinear mixed effect modeling to describe the PK profile of tocilizumab and used to estimate interindividual variability and assess the influence of covariates on PK parameters. The model was constructed based on data collected from 1793 patients with moderate to severe RA who received tocilizumab (4 or 8 mg/kg), via intravenous infusion every 4 weeks, during 4 phase III clinical trials. Serum concentration-time profiles of tocilizumab were adequately described by a 2-compartment disposition model with parallel linear and nonlinear elimination kinetics. The 8-mg/kg dose of tocilizumab, compared with the 4-mg/kg dose, resulted in a more pronounced saturation of the nonlinear clearance pathway over the dosing interval, and this nonlinear clearance was representative of target-mediated elimination due to tocilizumab binding to the IL-6 receptor.
19705790 [Asymptomatic carotid atherosclerosis and its predictors in patients with rheumatoid arthr 2009 The aim of this work was to study prevalence, severity, and possible pathogenetic mechanisms of asymptotic atherosclerotic lesions in carotid arteries of young and middle-aged patients with rheumatoid arthritis (RA). A total of 100 cases without clinical manifestations of atherosclerosis (AS) were examined. Risk factors (RF) of cardiovascular complications were analysed and stratified. Ultrasound scanning and dopplerography of carotid and vertebral arteries included measurement of common carotid arteries intima-media thickness. Echocardiographic studies were performed and ankle-brachial index (ABI) determined. The study revealed high frequency of asymptomatic increase of the intima-media thickness and carotid AS (in 55 and 18% of the cases respectively). These changes related to the patients" age, duration of RA, activity of immunoinflammatory processes, and traditional RF of cardiovascular complications. The findings provide a basis for the search of therapeutic modalities to correct the above lesions by controlling RA activity and modifying cardiovascular RF. The latent clinical course of RA and AS requires thorough instrumental studies for optimization of the treatment of such patients. Structural changes in carotid arteries in RA are associated with atherosclerotic lesions in the aorta, increased vascular wall stiffness (high ABI) and left ventricular hypertrophy. This implies that remodeling cardiovascular system during RA is an integrated pathological process. It is concluded that cardiovascular disturbances associated with RA should be regarded as a multifactor pathology resulting from persistent autoimmune inflammation and metabolic disorders.
20806409 Aberrant stress-induced Hsp70 expression in immune cells in multiple sclerosis. 2010 Nov 1 Heat shock protein 70 (Hsp70), a prominent member of the heat shock protein family, is a stress-induced chaperone, contributing to the "protein triage" mechanism. However, we and others have previously shown that chaperonin activity of Hsp70 also promotes immune recognition of protein/peptide antigens, including myelin autoantigens. Hsp70 has been strikingly elevated in multiple sclerosis (MS) lesions. In a search for the mechanism of Hsp70 up-regulation in MS, we analyzed Hsp70 expression in peripheral blood mononuclear cells (PBMCs) from MS patients (n = 49), healthy controls (n = 40), and patients with rheumatoid arthritis, (RA; n = 13). Hsp70 was detected by Western blot, and Hsp70 levels were quantified by ELISA. We found that Hsp70 was expressed at low levels in ex vivo PBMCs. However, after heat shock, Hsp70 was up-regulated significantly more (up to sixfold) in MS patients compared with healthy controls. This significant overproduction of Hsp70 was also seen following another stress condition, LPS stimulation. Hsp70 is a product of several independent genes, and we found the HSPA1B gene product to be the major form responsible for Hsp70 protein overexpression in PBMCs. Hsp70 overexpression was preceded by increased nuclear presence of heat shock factor 1 (HSF1). HSF1 activation depends on phosphorylation, and we found that inhibition of the A group of protein kinase C isoenzymes significantly reduced inducible Hsp70 production. These results indicate that immune cells from MS patients are more prone to Hsp70 induction under stress conditions, suggesting a possible link between Hsp70 overexpression and development of autoimmunity.
19473564 Potentiation of glucocorticoid receptor (GR)-mediated signaling by the immunosuppressant t 2009 Mar OBJECTIVE: The immunosuppressant tacrolimus is known to enhance many aspects of glucocorticoid. In this study, we investigated the effects of tacrolimus on glucocorticoid receptor (GR) signaling using rheumatoid fibroblast-like synoviocytes (RA-FLS). METHODS: The nuclear translocation of GR was analyzed by immunocytochemistry. The DNA binding activity of p65 was assayed by a functional ELISA kit using nuclear extracts. GR-associated FK506-binding protein-51 (FKBP-51) was analyzed by Western blotting following immunoprecipitation of glucocorticoid receptor (GR) complexes. RESULTS: High concentrations (10-7M) of Dexamethasone (Dex) induced GR translocation to the nucleus in RA-FLS. However, the nuclear GR translocation did not occur with low concentrations of Dex (10-9M). Tacrolimus treatment of RA-FLS results in potentiation of GR translocation to the nucleus even in the presence of a low concentration of Dex (10-9M). GR-associated FKBP-51 decreased after tacrolimus treatment. Furthermore, tacrolimus also decreased the IL-1Beta-induced DNA binding activity of p65, a subunit of NF-KappaB, in the presence of 10-9 M of Dex. CONCLUSION: These data suggest that tacrolimus exerts anti-inflammatory properties by potentiating the GR signaling through the GR-immunosuppressant-binding proteins (immunophilins) interaction and its nuclear transport in rheumatoid synovium.
19208595 Influence of an educational seminar on use of disease activity measurements by rheumatolog 2009 Mar OBJECTIVE: To determine the variables underlying clinical decisions made by rheumatologists when treating patients with rheumatoid arthritis (RA), and to determine the effect of an educational seminar on the use of quantitative disease activity measurements in clinical practice in this population of physicians. METHODS: Practicing rheumatologists were surveyed on the variables affecting their clinical management of patients with RA by questionnaire. Physicians were divided into 2 groups: the first comprised attenders (Group A) to an educational seminar in the use of the quantitative disease activity measurements in patient management, while the second group comprised nonattenders (Group NA). Both groups were surveyed on their practice behavior before (Survey 1) and 2 to 3 months after (Survey 2) the seminar. RESULTS: Fifty-two rheumatologists in clinical practice from across the US completed and returned 364 surveys. A significantly greater number of rheumatologists in Group A reported use of disease activity measures following the training seminar (Survey 2), compared to their use pre-meeting and compared to Group NA (p < 0.0001). CONCLUSION: Our results support employment of an educational seminar on the use of disease activity measurements to increase the use of these quantitative measures in rheumatologic practice.
19220165 The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. 2009 Apr OBJECTIVE: To quantify and compare direct costs, utilization, and the rate of comorbidities in a sample of patients with fibromyalgia (FM), a poorly understood illness associated with chronic widespread pain that is commonly treated by rheumatologists, to patients with rheumatoid arthritis (RA), a well studied rheumatologic illness associated with inflammatory joint pain. Patients with both illnesses were isolated and reported as a third group. A secondary analysis of work loss was performed for an employed subset of these patients. RESEARCH DESIGN AND METHODS: Retrospective cohort analysis of Thomson Reuters MarketScan administrative healthcare claims and employer-collected absence and disability data for adult patients with a diagnosis of FM (ICD-9-CM 729.1) and/or RA (ICD-9-CM 714.0x,-714.3x) on at least one inpatient or two outpatient claims during 2001-2004. MAIN OUTCOME MEASURES: The 12-month healthcare utilization, expenditures, and rates of comorbidities were quantified for all study-eligible patients; absence and short-term disability days and costs were quantified for an employed subset. RESULTS: The sample included 14034 FM, 7965 RA, and 331 FM+RA patients. Patients with FM had a higher prevalence of several comorbidities and greater emergency department (ED) utilization than those with RA. Mean annual expenditures for FM patients were $10911 (SD=$16075). RA patient annual expenditures were similar to FM: $10716 (SD= $16860). Annual expenditures were almost double in patients with FM+RA ($19395, SD= $25440). A greater proportion of patients with FM had any short-term disability days than those with RA (20 vs. 15%); and a greater proportion of patients with RA had any absence days (65 vs. 80%). Mean costs for absence from work and short-term disability in the FM and RA groups were substantial and similar. The FM+RA group was of insufficient sample size to report on work loss. LIMITATIONS: The availability of newer and more expensive FDA-approved medications since 2004 is not reflected in our findings. This analysis was restricted to commercially insured patients and therefore may not be generalizable to the entire U.S. population. CONCLUSIONS: The burden of illness in FM is substantial and comparable to RA. Patients with FM incurred direct costs approximately equal to RA patients. Patients with FM had more ED, physician, and physical therapy visits than RA patients. Patients in both groups had several comorbidities. Patients with FM+RA incurred direct costs almost double those of the patients with either diagnosis alone. FM and RA patients incurred similar overall absence and short-term disability costs.
19937040 [The High Priest of gout - Sir Alfred Baring Garrod (1819-1907)]. 2009 Dec The name of Sir Alfred Baring Garrod is linked with the first detection of uric acid in blood and its accumulation in sufferers from gout as well as the formulation of the term rheumatoid arthritis. The disease concept formulated by him initially (especially in Germany) caused confusion and much discussion but has now become accepted worldwide. Garrod's work on gout delivered important contributions to the elucidation of pathophysiological problems of the symptoms. Furthermore, he made a great contribution to the reorganization of the British Pharmacopoeia. One of his sons, the also knighted Sir Archibald Edward Garrod, initially continued the work of his father in the field of rheumatology and thereby made it really known. Later he developed his own research field with the establishment of the genetics of metabolism and introduced here the term inborn errors of metabolism.
19165120 Racial disparities in treatment preferences for rheumatoid arthritis. 2009 Mar BACKGROUND: Data suggest that differences in patient preferences may account for racial disparities in the use of medical interventions. Racial disparities have also been noted in outcomes and the delivery of healthcare services in chronic disease. Whether treatment preferences in chronic disease differ by race is not known. METHODS: We elicited treatment preferences for aggressive therapy in patients with rheumatoid arthritis who identified themselves as being black or white. RESULTS: One hundred fifty consecutive eligible patients were invited to participate. Of these, 136 subjects completed the interview. In unadjusted analysis, 51% of white participants preferred aggressive therapy compared with 16% of blacks (P < 0.0001). Subjects who were married and reported having at least some college education had stronger preferences for aggressive therapy compared with their respective counterparts. After adjusting for covariates, race remained the strongest predictor of aggressive therapy examined in this study [adjusted odds ratio (95% confidence interval) = 11.2 (1.9-64.9)]. CONCLUSIONS: In this study, fewer black patients preferred aggressive treatment compared with white patients with similar disease severity. These results have important clinical implications because use of aggressive treatment improves both short- and long-term outcomes in rheumatoid arthritis. Efforts to improve patient education and physician communication should be made to ensure that all patients have an accurate understanding of the benefits, as well as risks, associated with the best available treatment options.
19002544 Diagnostic utility of anti-cyclic citrullinated peptide antibodies for rheumatoid arthriti 2009 Mar This study was intended to evaluate the utility of anti-cyclic citrullinated peptide antibodies (second generation, anti-CCP2) as a diagnostic marker for rheumatoid arthritis (RA) in patients with active tuberculosis. Among 89 patients with active tuberculosis, anti-CCP2 was detected in six (6.7%), and three of these (3.4%) were strongly positive for anti-CCP2. The positive rate of anti-CCP2 in patients with newly diagnosed RA was 82.1% (87 of 106 cases), while the rate in healthy control subjects was 0.4% (one of 237 individuals). The mean level of anti-CCP2 among the RA group was 159.3 U/ml, which was significantly higher than both that among the tuberculosis group (15.4 U/ml) and that among the healthy controls (0.7 U/ml). IgM rheumatoid factor (RF) was detected in 16 patients from the tuberculosis group (18.0%) with a mean serum level of 18.6 IU/ml and in 77 patients of the RA group (72.6%) with a mean level of 164.0 IU/ml. Only two cases in the tuberculosis group were positive for both anti-CCP2 and IgM RF. These observations show that measurement of anti-CCP2 seems to be a reliable serological tool for identifying early RA in patients with active tuberculosis.
20169875 [The Polish model of physiotherapeutic conduct in rheumatoid arthritis and recommendation 2009 Sep THE AIM: The aim of the research was to evaluate how the suggestions of the Ottawa Panel are implemented with regard to the patents suffering from rheumatoid arthritis in Poland. MATERIAL AND METHOD: in the research there was a test group of 41 people (33 women and 8 men) with rheumatoid arthritis. The criterion that was decisive in this study was the phase of reemission of the illness and whether the patient was taking part in physiotherapeutic treatment. The age of the subjects varied from 25 and 79 (the average age was 53.11). The average duration of the illness was 12.17 years. The research was conducted from November 2006 until September 2007 in Wiktor Dega Orthopedic-Rehabilitation Clinical Hospital (O-RSK4) in Poznan and in 22nd Military Rehabilitation Hospital in Ciechocinek. RESULTS: It was shown in the tested group there was a deep correlation between the joints with movement restrictions and the ones that caused most pain (r = 0.6086 for sum of painful joints with those with movement restrictions). Any link between the presence of deformation within the lower limb and exercising the suggested elements of gait during rehabilitation has not been found. Similarly, there was no dependence between the presence of deformations in the upper limb and the appropriate physiotherapeutic treatment. However, only in one patient the physical treatment recommended by the Panel was not used at all. CONCLUSIONS: The majority of the Ottawa Panel recommendations is implemented in the Polish model. A big part of patients has access to rehabilitation and usually the physical treatment techniques that proved to be the most beneficial are used. However, certain changes should be introduced to kinesis therapy, which tends to be focused more on joint deformation than on global work on the improvement of functionality and thus--the quality of patient's life.
19369454 Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arth 2009 Aug OBJECTIVE: Studies have suggested that early institution of tumor necrosis factor (TNF) inhibitors improves functional status and slows radiographic progression among patients with rheumatoid arthritis (RA). To determine whether these findings have altered practice patterns, we used the Consortium of Rheumatology Researchers of North America (CORRONA) registry to assess the pattern of TNF inhibitor utilization in the US over time. METHODS: Demographics and disease activity data were collected for patients with RA. The trend of TNF inhibitor use during 2002-06 was evaluated prospectively using linear and logistic regression models. RESULTS: Of the 11,397 patients with RA, 66% and 34% had established RA and early RA (disease duration < 3 yrs), respectively. The majority of patients were female and Caucasian. Despite comparable levels of disease activity, more of the patients with established RA were taking TNF inhibitors than those with early RA (40% vs 25%; p < 0.0001). The majority of patients (70%) taking TNF inhibitors were also receiving disease modifying antirheumatic drugs. The use of TNF inhibitors increased at a rate of 2.8% per year in established RA and 1.2% per year in early RA. The mean Clinical Disease Activity Index at the start of TNF inhibitors decreased at a rate of -0.233 per quarter (p = 0.006), while the mean Disease Activity Score decreased at a rate of -0.04 per quarter (p = 0.022). CONCLUSION: Utilization of TNF inhibitors in this multicenter, observational US cohort is increasing in both early and established RA, although it is more prominent among patients with established RA. The level of disease activity at which TNF inhibitors were initiated decreased over time in patients with both established and early RA.
19758132 Seronegative autoimmune diseases. 2009 Sep A close relationship exists between autoimmunity and autoantibodies; despite this, some patients are persistently negative for disease-specific autoantibodies. These conditions have been defined as seronegative autoimmune diseases. Although the prevalence of seronegative autoimmune diseases is low, they may represent a practical problem because they are often difficult cases. There are also situations in which autoantibodies are positive in healthy subjects. In particular, three different conditions can be described: latent autoimmunity, preclinical autoimmunity, and postclinical autoimmunity. Here, we analyze briefly the meaning of autoantibody negativity in the seronegative autoimmune diseases, focusing in particular on the specificities associated with systemic lupus erythematosus, antiphospholipid syndrome, and rheumatoid arthritis.
20231785 Anti-cyclic citrullinated peptide antibodies are not associated with familial Mediterranea 2010 OBJECTIVE: This study investigated the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies in familial Mediterranean fever (FMF) patients and controls. MATERIAL AND METHODS: Forty-nine patients with FMF were enrolled (23 had a history of arthritis during attacks and 26 had no such history). Two control groups were enrolled: 20 patients with rheumatoid arthritis (RA) and 30 healthy individuals. Clinical and laboratory assessments of the FMF patients were performed during attack-free periods. Erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP), rheumatoid factor (RF), and anti-CCP antibody levels were measured. RESULTS: In RA patients' ESR and CRP levels, frequency of RF, and anti-CCP antibody levels were significantly higher than in both FMF patients and healthy controls (p 0.001). Moreover, anti-CCP was negative in all healthy controls as well as in all FMF patients. CONCLUSION: Our results show that anti-CCP antibodies are not associated with FMF.
21057839 Health-related quality of life in ankylosing spondylitis, fibromyalgia syndrome, and rheum 2011 May In this study, we compared health-related quality of life (HRQoL) scores of patients with rheumatoid arthritis (RA), fibromyalgia syndrome (FS), or ankylosing spondylitis (AS), with those of a selected sample of healthy individuals. The study group comprised 530 patients (264 with RA, 149 with FS, and 117 with AS). Three hundred fifteen healthy controls were used for comparison. HRQoL scores were obtained using the Short-Form (SF)-36 Health Survey. Frequency, mean, correlation, and multiple regression analyses were performed; in addition to the Student's t test, one-way ANOVA test, Kruskal-Wallis test, and chi-square test. The average physical component summary (PCS) and mental component summary (MCS) scores of patients in the RA, FS, and AS groups were much lower than those in the control group (p < 0.05). In all three patient groups, the lowest PCS score was found in the RA group, and the lowest MCS score was found in the FS group. The PCS scores of RA patients with disease-related changes in daily activities and the MCS scores of FS patients were lower (p < 0.05). In the three patient groups, the quality of life (QoL) of university graduates and those with a high level of income was good, whereas the QoL of patients who lacked information about the disease was poor. This study shows that AS, FS, and RA have a negative impact on HRQoL. Evaluating the HRQoL of patients with these conditions may provide guidance on their treatment and care.
19229765 Interleukin-18 gene (IL18) promoter polymorphisms in patients with rheumatoid arthritis. 2009 May OBJECTIVE: Rheumatoid arthritis (RA) is a complex autoimmune disease with a strong genetic contribution to its pathogenesis. Proinflammatory cytokines play an important role in the inflammatory process in RA patients. The synthesis of cytokines is genetically determined. Cytokine gene polymorphisms have been implicated in a number of diseases, including RA. Interleukin-18 (IL-18) is a proinflammatory cytokine involved in the pathogenesis of RA. There are, however, controversial reports that the IL18 promoter polymorphism may be an independent marker of RA susceptibility. The aim of the present study was to examine the IL18 promoter polymorphism in patients with RA in association with disease susceptibility and activity. METHODS: We examined 404 patients with RA diagnosed according to the criteria of the American College of Rheumatology (ACR). Allele-specific polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (RFLP) methods were used to analyse the single-nucleotide polymorphisms (SNPs) rs1946518, rs187238, rs360718, rs360722, rs360721, rs549908, and rs5744292 in the promoter region of the IL18 gene. RESULTS: There were no significant differences in the distributions of the genotypes and haplotypes between RA patients and a control group. Age at RA diagnosis was lower in carriers of the rs1946518 CC and rs187238 GG genotypes. Erosive disease was diagnosed more frequently in patients with the rs1946518 CC and AC genotypes than in AA homozygotes. CONCLUSION: These results show that these polymorphisms in the IL18 gene are associated only with some disease parameters and are generally not factors significantly influencing the course of RA.
19228650 Association of polymorphisms in interferon regulatory factor 5 gene with rheumatoid arthri 2009 Apr OBJECTIVE: We investigated potential associations between rheumatoid arthritis (RA) and interferon regulatory factor 5 (IRF5) polymorphisms in a metaanalysis. METHODS: This metaanalysis included 5 case-control studies, which provided a total of 6582 RA cases and 5375 controls. Odds ratios (OR) were employed to evaluate the risk of RA according to the 4 single-nucleotide polymorphisms (SNP) in IRF5 (rs729302, rs2004640, rs752637, and rs2280714) and data were analyzed in respect to association between alleles. RESULTS: Among 4 candidate SNP, rs729302, rs2004640, and rs2280714 were statistically significant; both allele C of rs729302 and allele G of rs2004640 within the promoter region of IRF5 were associated with a protective effect [random-effects (RE) OR 0.889, 95% confidence interval (CI) 0.803-0.977, p=0.015 for rs729302; and RE OR 0.905, 95% CI 0.848-0.965, p=0.002 for rs2004640]. Similar results were also obtained in T allele of rs2280714 in the 3'-untranslated region (RE OR 0.927, 95% CI 0.866-0.992, p=0.029). There was no evidence of publication bias from funnel-plot asymmetry and Egger's regression test. CONCLUSION: Our metaanalysis supported the evidence of the significant role of IRF5 polymorphisms in RA.
20490888 β1,4-Galactosyltransferase-I contributes to the inflammatory processes in synovial tissue 2010 Dec OBJECTIVE AND DESIGN: The aim of the study is to examine the expression and possible biological function of β1,4-galactosyltransferase-I (β1,4-GalT-I) in synovial tissue from rheumatoid arthritis (RA) patients. METHODS: Synovial tissue samples from twelve RA patients were stained for β1,4-GalT-I. Samples from seven patients with osteoarthritis (OA) and eight healthy people were obtained as controls. Real-time PCR or western blot analysis was used to observe the expression of β1,4-GalT-I and E-selectin. Cellular colocalization of β1,4-GalT-I, galactose-containing glycans and other molecules was analyzed by double immunofluorescence. RESULTS: Expression of β1,4-GalT-I and galactose-containing glycans increased in synovial tissue of RA patients compared with OA patients and healthy controls. Most galactose-containing glycans and β1,4-GalT-I were expressed in inflammatory cells. E-selectin overexpressed and was correlated with galactose-containing glycans in RA synovial tissue. CONCLUSION: These results suggested that β1,4-GalT-I may play an important role in the inflammatory processes in synovial tissue of patients with rheumatoid arthritis.